Abstracts tagged "abatacept and biomarkers"

Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 1390 • 2019 ACR/ARP Annual Meeting
Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels
Silvia Piantoni¹, Michele Boldini ¹, Rajesh Kumar ¹, Emirena Garrafa ¹, Chiara Bazzani ², Micaela Fredi ³, Ilaria Cavazzana ¹, Angela Tincani ³ and Franco Franceschini ³, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: Carbamylation is a non-enzymatic irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). In…
Abstract Number: 2067 • 2015 ACR/ARHP Annual Meeting
De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus
S Bandyopadhyay¹, SE Connolly¹, O Jabado¹, S Kelly¹, M Maldonado¹, R Westhovens², P Nash³, JT Merrill⁴ and R Townsend¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University Hospitals KU Leuven, Leuven, Belgium, ³University of Queensland, Brisbane, Australia, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Phase IIb IM101-042 trial was a randomized, double-blind, placebo-controlled trial of abatacept (ABA) in systemic lupus erythematosus patients (pts) with polyarthritis, discoid lesions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].